EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models
Patrizia Porazzi(Sidney Kimmel Cancer Center), Marco Ruella(University of Pennsylvania), Ositadimma Ugwuanyi(Hospital of the University of Pennsylvania), Ruchi P. Patel(Parker Institute for Cancer Immunotherapy), Gregory L. Beatty(University of Pennsylvania), Yusuke Isshiki(Cornell University), Linhui Chen(Hospital of the University of Pennsylvania), Ari Melnick(Cornell University), Alberto Carturan(Hospital of the University of Pennsylvania), Mathew G. Angelos(University of Pennsylvania), Devora Delman(Hospital of the University of Pennsylvania), Guido Ghilardi(Hospital of the University of Pennsylvania), Luca Paruzzo(Hospital of the University of Pennsylvania), Puneeth Guruprasad(Parker Institute for Cancer Immunotherapy), Eugenio Fardella(Hospital of the University of Pennsylvania), Tatiana Blanchard(University of Pennsylvania), Olga Shestova(University of Pennsylvania), Jean Lemoine(Université Sorbonne Paris Nord), Melody T. Tan(Parker Institute for Cancer Immunotherapy), Kelly Markowitz(Hospital of the University of Pennsylvania), Gerald P. Linette, Stephen J. Schuster(UPMC Hillman Cancer Center), Raymone Pajarillo(Hospital of the University of Pennsylvania), Wendy Béguelin(Cornell University), Yunlin Zhang(Hospital of the University of Pennsylvania), A. Padmanabhan(Hospital of the University of Pennsylvania), Beatriz M. Carreno(Parker Institute for Cancer Immunotherapy), Ivan Cohen(Hospital of the University of Pennsylvania), Siena Nason(Hospital of the University of Pennsylvania)
Cited by 47
Related Papers
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
|The Journal of Experimental Medicine|2000|5.2k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|2.9k
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k